Published January 2026
Below is a list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee. For coverage information regarding these medications, please review the MVP Formularies available at Pharmacy Information for Providers . For more detailed information regarding pharmacy changes, please review Provider FastFax Library or visit all policies MVP Health Care Medical Policy.
A list of formulary changes for Plan Year 2025 is available for review: 2025 Commercial and Marketplace Formulary Changes. Changes will take effect on the member’s pharmacy “Plan Year” start date.
Drugs removed from prior authorization for Commercial, Marketplace, and Self-Funded Formularies
- Grafapex
- Xromi
- Zunveyl
- Inzirqo
- Revuforj
- Rapiblyk
- Tezruly
- Zevtera
- Avmapki
- Emblaveo
- Khindivi
New Drugs excluded for Commercial, Marketplace, and Self-Funded Formularies
- Alhemo
- Raldesy
- Vanrafia
- Qfitlia
- Symbravo
New generics that recently came to market
| Brand name | Generic name |
|---|---|
| Xarelto | Rivaroxaban suspension |
| Eprontia | Topiramate solution |
| Dificid | Fidaxomicin tablet |
| Venofer injection; | Iron Sucrose |
| Arnuity Ellipta | Fluticasone Furoate |
| Saxenda | Liraglutide |
Policy Updates
Review other articles in this issue regarding formulary, pharmacy policy, and medical policy updates.